Ipsen SA

Ipsen SA, a Paris‑based biopharma founded in 1929, delivers oncology, rare‑disease and neuroscience drugs. Approved assets include Somatuline, Cabometyx, Onivyde and Decapeptyl, with phase‑III Tazverik and dysport expanding its growth pipeline.

Headquarters: France (FRA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical and Diagnostic Laboratories

Employees: 5,358
HQ: Paris

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
IPN	Ipsen SA Cap: 10.7B \| P/E: 24.1	EQUITY	PAR	EUR	FR0010259150	Active	📈